Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action

Progress in Neurobiology

Volumn 58, Issue 1, 1999, Pages 31-59

  Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; ATAXIA; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; EPILEPSY; GABAERGIC TRANSMISSION; HUMAN; LIVER TOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SEDATION; SEROTONINERGIC SYSTEM; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; TREMOR;

EID: 0037742375     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(98)00075-6     Document Type: Review

References (238)

1. Abbott F. S., Acheampong A. A. Quantitative structure-anticonvulsant activity relationships of valproic acid, related carboxylic acids and tetrazoles. Neuropharmacology. 27:1988;287-294.
2. Adkison K. D. K., Shen D. D. Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J. Pharmacol. Exp. Ther. 276:1996;1189-1200.
3. Adkison K. D. K., Ojemann G. A., Rapport R. L., Dills R. L., Shen D. D. Distribution of unsaturated metabolites of valproate in human and rat brain - pharmacologic relevance? Epilepsia. 36:1995;772-782.
4. Albus H., Williamson R. W. Electrophysiological analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia. 39:1998;124-139.
5. Altrup U., Gerlach G., Reith H., Said M. N., Speckmann E. J. Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia): I. Antiepileptic actions. Epilepsia. 33:1992;743-752.
6. Baf M. H. M., Subhash M. N., Lakshmana K. M., Rao B. S. S. R. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 24:1994;67-72.
7. Baillie, T. A. and Levy, R. H. (1991) Metabolic fate of valproic acid in humans. In: Idiosyncratic Reactions to Valproate. Clinical Risk Patterns and Mechanism of Toxicity, pp. 19-24. Eds. R. H. Levy and J. K. Penry. Raven Press, New York.
8. Baillie, T. A. and Sheffels, P. R. (1995) Valproic acid. Chemistry and Biotransformation. In: Antiepileptic Drugs, 4th edn, pp. 589-604. Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
9. Baldino F., Geller H. M. Effect of sodium valproate on hypothalamic neurons in vivo and in vitro. Brain Res. 219:1981;231-237.
10. Baldwin G. S., Abbott F. S., Nau H. Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. FEBS Lett. 384:1996;58-60.
11. Balfour J. A., Bryson H. M. Valproic acid - a review of its pharmacology and therapeutic potential in indications other than epilepsy. Cns. Drugs. 2:1994;144-173.
12. Biggs C. S., Pearce B. R., Fowler L. J., Whitton P. S. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus: an in vivo microdialysis study. Brain Res. 594:1992;138-142.
13. Biggs C. S., Pearce B. R., Fowler L. J., Whitton P. S. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J. Neurochem. 59:1992;1702-1708.
14. Blackshear P. J. The MARCKS family of cellular rotein kinase C substrates. J. Biol. Chem. 268:1993;1501-1504.
15. Bolanos J. P., Medina J. M. Evidence of stimulation of the gamma-aminobutyric acid shunt by valproate and E-delta-2-valproate in neonatal rat brain. Mol. Pharmac. 43:1993;487-490.
16. Burton B. S. On the propyl derivatives and decomposition products of ethylacetoacetate. Am. Chem. J. 3:1882;385-395.
17. Carraz G., Fiorina S. Activation de la formation d'anti corps par le système réticuloendothelial. Ann. Biol. Clin. (Paris). 76:1967;187.
18. Carraz G., Fau R., Chateau R., Bonnin J. Communication à propos des premiers essais cliniques sur l'activité anti-épileptique de l'acide n-dipropylacétiques (sel de Na). Ann. Med. Psychol. (Paris). 122:1964;577-585.
19. Chapman A., Keane P. E., Meldrum B. S., Simiand J., Vernieres J. C. Mechanism of anticonvulsant action of valproate. Progr. Neurobiol. 19:1982;315-359.
20. Chapman A. G., Meldrum B. S., Mendes E. Acute anticonvulsant activity of structural analogues of valproic acid and changes in brain GABA and aspartate content. Life Sci. 32:1983;2023-2031.
21. Clark, S. and Wilson, W. A. (1992) Brain slice model of epilepsy: Neuronal networks and actions of antiepileptic drugs. In: Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders, pp. 89-124. Eds. C. L. Faingold and G. H. Fromm. CRC Press, Boca Raton.
22. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 22:1981;489-501.
23. Commission on Classification and Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 30:1989;389-399.
24. Concas A., Mascia M. P., Sanna E., Santoro G., Serra M., Biggio G. 'In vivo' administration of valproate decreases t[35S]butylbicyclophosphorothionate binding in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmac. 343:1991;296-300.
25. Cotariu D., Zaidman J. L., Evans S. Neurophysiological and biochemical changes evoked by valproic acid in the central nervous system. Progr. Neurobiol. 34:1990;343-354.
26. Coulter D. A., Huguenard J. R., Prince D. A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann. Neurol. 25:1989;582-593.
27. Cowan A. RX 366-M, a new chemical tool in the analysis of the quasi-morphine with drawal syndrome. Fed. Proc. 40:1981;1497-1501.
28. Cowan A., Watson T. Lysergic acid diethylamide antagonizes shaking induced in rats by five chemically different compounds. Psychopharmacology. 57:1978;43-46.
29. 2+ uptake and amino acid neurotransmitter release in vitro. Epilepsia. 28:1987;378-382.
30. Cutrer F. M., Limmroth V., Moskowitz M. A. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 17:1997;93-100.
31. Czuczwar S. J., Frey H.-H., Löscher W. Antagonism of N-methyl-D,L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur. J. Pharmac. 108:1985;273-280.
32. Dailey J. W., Jobe P. C. Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed. Proc. 44:1985;2640-2644.
33. Davis R., Peters D. H., Mctavish D. Valproic acid - a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 47:1994;332-372.
34. De Boer T., Metselaar H. J., Briunvels J. Suppression of GABA-induced abstinence behaviour in naive rats by morphine and bicuculline. Life Sci. 20:1977;933-942.
35. De Souza Queiroz M. L., Mullen P. W. The effects of phenytoin, 5-(parahydroxy phenyl)-5-phenylhydantoin, and valproic acid on humoral immunity in mice. Int. J. Immunopharmac. 2:1980;224-225.
36. DeFeudis F. V. Gamma-aminobutyric acid-ergic analgesia: implications for gamma-aminobutyric acid-ergic therapy for drug addiction. Drug Alcohol Depend. 14:1984;101-111.
37. Dixon J. F., Hokin L. E. The antibipolar drug valproate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc. natl Acad. Sci. USA. 94:1997;4757-4760.
38. Dreier J. P., Heinemann U. Late low magnesium-induced epileptiform activity in rat entorhinal cortex slides becomes insensitive to the anticonvulsant valproic acid. Neurosci. Lett. 119:1990;68-70.
39. Ekwuru M. O., Cunningham J. R. Phaclofen increases GABA release from valproate treated rats. Br. J. Pharmac. 99(Suppl.):1990;251P.
40. Emrich H. M., von Zerssen D., Kissling W., Moeller H. J., Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr. 229:1980;1-16.
41. Evans, M. S. (1992) Overview of actions of antiepileptic drugs on repetitive neuronal firing. In: Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders, pp. 69-88. Eds. C. L. Faingold and G. H. Fromm. CRC Press, Boca Raton.
42. Fariello, R. G., Varasi, M., and Smith, M. C. (1995) Valproic acid. Mechanisms of action. In: Antiepileptic Drugs, 4th edn, pp. 581-604. Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
43. Farrant M., Webster R. A. Neuronal activity, amino acid concentration and amino acid release in the substantia nigra of the rat after sodium valproate. Brain Res. 504:1989;49-56.
44. 2+]0 and [K+]0 in the hippocampal slice. Brain Res. 386:1986;1-11.
45. Fredow G., Löscher W. Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia. Eur. J. Pharmac. 192:1991;207-219.
46. Frey H.-H., Löscher W. Di-n-propylacetic acid-profile of anticonvulsant activity in mice. Arzneim.-Forsch. (Drug Res.). 26:1976;299-301.
47. Frey H.-H., Löscher W. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology. 17:1978;637-642.
48. Frey H.-H., Löscher W., Reiche R., Schultz D. Anticonvulsant potency of common antiepileptic drugs in the gerbil. Pharmacology. 27:1983;330-335.
49. Fromm, G. H. (1992) Antiepileptic actions of valproate. In: Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders, pp. 453-462. Eds. C. L. Faingold and G. H. Fromm. CRC Press, Boca Raton.
50. Gean P. W., Huang C. C., Hung C. R., Tsai J. J. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res. Bull. 33:1994;333-336.
51. Gent J. P., Phillips N. I. Sodium di-n-propylacetate (valproate) potentiates responses to GABA and muscimol on single central neurons. Brain Res. 197:1980;275-278.
52. Gent J. P., Bentley M., Feely M., Haigh J. R. M. Benzodiazepine cross-tolerance in mice extends to sodium valproate. Eur. J. Pharmac. 128:1986;9-15.
53. Godin Y., Heiner L., Mark J., Mandel P. Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. J. Neurochem. 16:1969;869-873.
54. Gram L., Larsson O. M., Johnsen A. H., Schousboe A. Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res. 2:1988;87-95.
55. Hammond E. J., Wilder B. J., Bruni J. Central actions of valproic acid in man and in experimental models of epilepsy. Life Sci. 29:1981;2561-2574.
56. Harrison N. L., Simmonds M. A. Sodium valproate enhances responses to GABA receptor activation only at high concentrations. Brain Res. 250:1982;201-204.
57. Hauck R.-S., Nau H. Zu den strukturellen Grundlagen der teratogenen Wirkung des Antiepileptikums Valproinsäure (VPA). Naturwissenschaften. 76:1989;528-529.
58. Hauck R.-S., Nau H., Elmazar M. M. A. On the development of alternative antiepileptic drugs. Naturwissenschaften. 78:1991;272-274.
59. Hauck R.-S., Elmazar M. M. A., Plum C., Nau H. The enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-yn-VPA) is due to stereoselective intrinsic activity and not differences in pharmacokinetics. Toxic. Lett. 60:1992;145-153.
60. Heinemann U., Draguhn A., Ficker E., Stabel J., Zhang C. L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia. 35(Suppl. 5):1994;S10-S21.
61. Hernandez T. D. Preventing post-traumatic epilepsy after brain injury: weighing the costs and benefits of anticonvulsant prophylaxis. Trends Pharmac. Sci. 18:1997;59-62.
62. Hoeppner T. J. The anticonvulsant valproic acid concentrates in the olfactory bulb: selective laminar localization. Brain Res. 532:1990;326-328.
63. Hönack D., Löscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res. 13:1992;215-221.
64. Horton R. W., Anlezark G. M., Sawaya M. C. B., Meldrum B. S. Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. Eur. J. Pharmac. 41:1977;387-397.
65. Hwang E. C., van Woert M. H. Effect of valproic acid on serotonin metabolism. Neuropharmacology. 18:1979;391-397.
66. Iadarola M. J., Gale K. Dissociation between drug-induced increases in nerve terminal and non-nerve terminal pools of GABA in vivo. Eur. J. Pharmac. 59:1979;125-129.
67. Iadarola M. J., Gale K. Cellular compartments of GABA in brain and their relationship to anticonvulsant activity. Mol. Cell. Biochem. 39:1981;305-330.
68. Iadarola M. J., Raines A., Gale K. Differential effects of n-dipropylacetate and aminooxyacetic acid on γ-aminobutyric acid levels in discrete areas of rat brain. J. Neurochem. 33:1979;1119-1123.
69. Jancovic, J. and Fahn, S. (1988) Dystonic syndromes. In: Parkinson's Disease and Movement Disorders, pp. 283-314. Eds. J. Jancovic and E. Tolosa. Urban and Schwarzenbek, Baltimore.
70. Johnston D. Valproic acid: update of its mechanism of action. Epilepsia. 24(Suppl. 1):1984;S1-S4.
71. Jurna, I. (1985) Electrophysiological effects of antiepileptic drugs. In: Antiepileptic Drugs, pp. 611-658. Eds. H.-H. Frey and D. Janz. Springer, Berlin.
72. Kelly K. M., Gross R. A., Macdonald R. L. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci. Lett. 116:1990;1-2.
73. Kerwin R. W., Taberner P. V. The mechanism of action of sodium valproate. Gen. Pharmac. 12:1981;71-75.
74. Kerwin R. W., Olpe H. R., Schmutz M. The effect of sodium-n-dipropylacetate on γ-aminobutyric acid-dependent inhibition in the rat cortex and substantia nigra in relation to its anticonvulsant activity. Br. J. Pharmac. 71:1980;545-551.
75. Kesterson J. W., Grannemann G. R., Machinist J. M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology. 4:1984;1143-1152.
76. Kingsley E., Gray P., Tolman K. G., Tweedale R. The toxicity of metabolites of sodium valproate in cultured hepatocytes. J. Clin. Pharmac. 23:1983;178-185.
77. Krall R. L., Penry J. K., White B. G., Kupferberg H. J., Swinyard E. A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia. 19:1978;409-428.
78. Kumlien E., Sherif F., Ge L., Oreland L. Platelet and brain GABA-transaminase and monoamine oxidase activities in patients with complex partial seizures. Epilepsy Res. 20:1995;161-170.
79. Kupferberg, H. J. (1980) Sodium valproate. In: Antiepileptic Drugs: Mechanism of Action, pp. 643-654. Eds. G. H. Glaser, J. K. Penry and D. M. Woodbury. Raven Press, New York.
80. Kuruvilla A., Uretsky N. J. Effect of sodium valproate on motor function regulated by the activation of GABA receptors. Psychopharmacology. 72:1981;167-172.
81. van der Laan J. W., De Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J. Neurochem. 32:1979;1769-1780.
82. van der Laan J. W., Jacobs A. W. C., Briunvels J. Effects of branched-chain fatty acids on GABA-degradation and behavior: further evidence for a role of GABA in quasi-morphine abstinence behavior. Pharmac. Biochem. Behav. 13:1980;843-849.
83. Lal H., Shearman G. T. Effect of valproic acid on anxiety-related behaviours in the rat. Brain Res. Bull. 5(Suppl. 2):1980;575-577.
84. Larsson O. M., Gram L., Schousboe I., Schousboe A. Differential effects of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurons and astrocytes. Neuropharmacology. 25:1986;617-625.
85. Levy, R. H. and Penry, J. K. (1991) Idiosyncratic Reactions to Valproate. Clinical Risk Patterns and Mechanisms of Toxicity. Raven Press, New York.
86. Levy, R. H. and Shen, D. D. (1995) Valproic acid. Absorption, distribution, and excretion. In: Antiepileptic Drugs, 4th edn, pp. 605-619. Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
87. Liljequist S., Engel J. A. Reversal of anticonflict action of valproate by various GABA and benzodiazepine antagonists. Life Sci. 34:1984;2525-2531.
88. Lloyd K. G., Thuret F., Pilc A. Upregulation of gamma-aminobutyric (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J. Pharmac. Exp. Ther. 235:1985;191-199.
89. Lockard, J. S., Levy, R. H., Koch, K. M., Maris, D. O., and Friel, P. N. (1983) A monkey model for status epilepticus: carbamazepine and valproate compared to three standard anticonvulsants. In: Status Epilepticus, pp. 411-419. Eds. A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman and R. J. Porter. Raven Press, New York.
90. Löscher W. Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA. J. Neurochem. 34:1980;1603-1608.
91. Löscher W. A comparative study of the pharmacology of inhibitors of GABA-metabolism. Naunyn-Schmiedeberg's Arch. Pharmac. 315:1980;119-128.
92. Löscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem. Pharmac. 30:1981;1364-1366.
93. Löscher W. Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions. J. Neurochem. 36:1981;1521-1527.
94. Löscher, W. (1982a) GABA in plasma, CSF and brain of dogs during acute and chronic treat ment with γ-acetylenic GABA and valproic acid. In: Problems in GABA Research - From Brain to Bacteria, pp. 102-109. Eds. Y. Okada and E. Roberts. Exerpta Medica, Amsterdam.
95. Löscher W. Cardiovascular effects of GABA, GABA-aminotransferase inhibitors and valproic acid following systemic administration in rats, cats and dogs: pharmacological approach to localize the site of action. Arch. Int. Pharmacodyn. Ther. 257:1982;32-58.
96. Löscher, W. (1985) Valproic acid. In: Antiepileptic Drugs, pp. 507-536. Eds. H.-H. Frey and D. Janz. Springer Verlag, Berlin.
97. Löscher, W. (1989a) GABA and the epilepsies. Experimental and clinical considerations. In: GABA. Basic Research and Clinical Applications, pp. 260-300. Eds. N. G. Bowery and G. Nisticò. Pythagora Press, Rome.
98. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 501:1989;198-203.
99. Löscher, W. (1991) Anticonvulsant Drug Mechanisms. In: Physiology, Pharmacology and Development of Epileptogenic Phenomena, pp. 193-200. Eds. M. R. Klee, H. D. Lux and E.-J. Speckmann. Springer-Verlag, Berlin.
100. 2(E)-valproate in animals. Pharm. Weekblad. 14:1992;139-143.
101. Löscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem. Res. 18:1993;485-502.
102. Löscher W. In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats. Neurosci. Lett. 160:1993;177-180.
103. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 53:1997;239-258.
104. Löscher W. New visions in the pharmacology of anticonvulsion. Eur. J. Pharmac. 342:1998;1-13.
105. Löscher, W. (1998b) Valproate. Birkhäuser, Basel, in press.
106. Löscher W., Ebert U. The role of the piriform cortex in kindling. Progr. Neurobiol. 50:1996;427-481.
107. Löscher W., Frey H.-H. Zum Wirkungsmechanismus von Valproinsäure. Arzneimittel-Forsch. 27:1977;1081-1082.
108. Löscher W., Frey H.-H. Effect of convulsant and anticonvulsant agents on level and metabolism of γ-aminobutyric acid in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmac. 296:1977;263-269.
109. Löscher W., Frey H.-H. Kinetics of penetration of common antiepileptics drugs into cerebrospinal fluid. Epilepsia. 25:1984;346-352.
110. Löscher W., Hönack D. Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats. Epilepsia. 36:1995;929-937.
111. Löscher W., Hönack D. Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. Eur. J. Pharmac. 299:1996;61-67.
112. Löscher W., Hörstermann D. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn-Schmiedeberg's Arch. Pharmac. 349:1994;270-278.
113. Löscher W., Meldrum B. S. Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. Fed. Proc. 43:1984;276-284.
114. Löscher W., Nau H. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice. Arch. Int. Pharmacodyn. Ther. 257:1982;20-31.
115. Löscher W., Nau H. Distribution of valproic acid and its metabolites in various brain regions of dogs and rats after acute and prolonged treatment. J. Pharmac. Exp. Ther. 226:1983;845-854.
116. Löscher W., Nau H. Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences. Arch. Int. Pharmacodyn. Ther. 270:1984;192-202.
117. Löscher W., Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Neurophamacology. 24:1985;427-435.
118. Löscher W., Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. J. Pharmac. exp. Ther. 258:1991;483-489.
119. Löscher W., Schmidt D. Increase of human plasma GABA by sodium valproate. Epilepsia. 21:1980;611-615.
120. Löscher W., Schmidt D. Plasma GABA levels in neurological patients under treatment with valproic acid. Life Sci. 28:1981;2383-2388.
121. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
122. Löscher W., Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17:1994;95-134.
123. Löscher W., Siemes H. Valproic acid increases γ-aminobutyric acid in CSF of epileptic children. Lancet. 2:1984;225.
124. Löscher W., Siemes H. Cerebrospinal fluid γ-aminobutyric acid levels in children with different types of epilepsy: effect of anticonvulsant treatment. Epilepsia. 26:1985;314-319.
125. Löscher W., Vetter M. In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities. Biochem. Pharmac. 34:1985;1747-1756.
126. Löscher W., Böhme G., Schäfer H., Kochen W. Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings. Neuropharmacology. 20:1981;1187-1192.
127. Löscher W., Nau H., Marescaux C., Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur. J. Pharmac. 99:1984;211-218.
128. Löscher W., Schwartz-Porsche D., Frey H.-H., Schmidt D. Evaluation of epileptic dogs as an animal model of human epilepsy. Arzneim.-Forsch. (Drug Res.). 35:1985;82-87.
129. Löscher W., Jäckel R., Czuczwar S. J. Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp. Neurol. 93:1986;211-226.
130. Löscher W., Fisher J. E., Nau H., Hönack D. Marked increase in anticonvulsant activity but decrease in wet-dog shake behaviour during short-term treatment of amygdala-kindled rats with valproic acid. Eur. J. Pharmac. 150:1988;221-232.
131. Löscher W., Nau H., Siemes H. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy. Epilepsia. 29:1988;311-316.
132. Löscher W., Fisher J. E., Nau H., Hönack D. Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. J. Pharmac. exp. Ther. 250:1989;1067-1078.
133. Löscher W., Wahnschaffe U., Hönack D., Wittfoht W., Nau H. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies. Epilepsy Res. 13:1992;187-198.
134. Löscher W., Rundfeldt C., Hönack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 15:1993;207-219.
135. Löscher W., Nau H., Wahnschaffe U., Hönack D., Rundfeldt C., Wittfoht W., Bojic U. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication. Epilepsy Res. 15:1993;113-131.
136. Löscher W., Wahnschaffe U., Hönack D., Drews E., Nau H. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting. Epilepsy Res. 16:1993;183-194.
137. Luder A. S., Parks J. K., Frerman F., Parker W. D. J. Inactivation of beef brain α-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. J. Clin. Invest. 86:1990;1574-1581.
138. Lust W. D., Kupferberg H. J., Yonekawa W. D., Penry J. K., Passoneau J. V., Wheaton A. B. Changes in brain metabolites induced by convulsants or electroshock: effects of anticonvulsant agents. Mol. Pharmac. 14:1978;347-356.
139. Macdonald R. L. Antiepileptic drug action. Epilepsia. 30(Suppl. 1):1989;S19-S28.
140. Macdonald R. L., Bergey G. K. Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res. 170:1979;558-562.
141. Macdonald R. L., Kelly K. M. Antiepileptic drug mechanisms of action. Epilepsia. 36:1995;S2-S12.
142. Macdonald, R. L. and McLean, M. J. (1986) Anticonvulsant drugs: mechanisms of action. In: Basic Mechanisms of the Epilepsies. Molecular and Cellular Approaches, pp. 713-736. Eds. A. V. Delgado-Escueta, A. A. J. Ward, D. M. Woodbury and R. J. Porter. Raven Press, New York.
143. Macdonald, R. L. and Meldrum, B. S. (1995) Principles of antiepileptic drug action. In: Antiepileptic Drugs, 4th edn, pp. 61-78. Eds. R. H. Levy, R. H. Mattson and B. S. Meldrum. Raven Press, New York.
144. Maes M., Calabrese J., Jayathilake K., Meltzer H. Y. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for in creased central serotonergic neurotransmission. Psychiat. Res. 71:1997;67-76.
145. Maitre M., Ossola L., Mandel P. In vitro studies into the effect of inhibition of rat brain succinic semialdehyde dehydrogenase on GABA synthesis and degradation. FEBS Lett. 72:1976;53-57.
146. Maitre M., Ciesielski L., Cash C., Mandel P. Comparison of the structural characteristics of the 4-aminobutyrate:2-oxoglutarate transaminases from rat and human brain, and of their affinities for certain inhibitors. Biochim. Biophys. Acta. 522:1978;385-399.
147. Martin-Gallard A., Rodriguez P., Lopet M., Benavides J., Ugarte M. Effects of dipropylacetate on the glycine cleavage enzyme system and glycine levels. Biochem. Pharmac. 34:1985;2877-2882.
148. McCandless D. W., Feussner G. K., Lust W. D., Passoneau J. V. Metabolite levels in brain following experimental seizures: the effects of isoniazid and sodium valproate in cerebellar and cerebral cortical layers. J. Neurochem. 32:1979;755-760.
149. McLean M. J., Macdonald R. L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmac. exp. Ther. 237:1986;1001-1011.
150. Meldrum B. Mechanism of action of valproate. Brain Res. Bull. 5(Suppl. 2):1980;579-584.
151. Meunier H., Carraz G., Meunier Y., Eymard P., Aimard M. Propriétés pharmacodynamiques de l'acide n-dipropylacétique. 1er Mémoire: propriétés antiépileptiques. Thérapie. 18:1963;435-438.
152. Miller L. G., Greenblatt D. J., Barnhill J. G., Summer W. R., Shader R. I. "GABA shift" in vivo: enhancement of benzodiazepine binding in vivo by modulation of endogenous GABA. Eur. J. Pharmac. 148:1988;123-130.
153. Mimaki T., Yabucchi W., Laird H., Yamamura H. I. Effects of seizures and anti epileptic drugs on benzodiazepine receptors in rat brain. Pediatr. Pharmac. 4:1984;205-211.
154. Morre M., Keane P. E., Vernières J. C., Simiand J., Ronucci R. Valproate: recent findings and perspectives. Epilepsia. 25(Suppl. 1):1984;S5-S9.
155. Motohashi N. GABA receptor alterations after chronic lithium administration - comparison with carbamazepine and sodium valproate. Prog. Neuro-Psych. Biol. Psychiat. 16:1992;571-579.
156. Mußhoff U., Madeja M., Düsing R., Speckmann E.-J. Valproate affects glutamate but not GABA receptors. Eur. J. Neurosci. 9(Suppl.):1996;205.
157. Nagao T., Oshimo T., Mitsunobo K., Sato M., Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients witgh tardive dyskinesia or drug-induced tremor. Biol. Psychiatr. 14:1979;509-523.
158. Nathanson J. A. Cyclic nucleotides and nervous system function. Physiol. Rev. 57:1977;157-256.
159. Nau H. Species differences in phamacokinetics and drug teratogenesis. Environment. Health Persp. 70:1986;113-129.
160. Nau H., Hendrickx A. G. Valproic acid teratogenesis. ISI Atlas Sci. 1:1987;52-54.
161. Nau H., Löscher W. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and GABA metabolism in the mouse. J. Pharmac. exp. Ther. 220:1982;654-659.
162. Nau H., Löscher W. Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia. 25(1):1984;14-22.
163. Nau H., Löscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice. Fund. Appl. Toxic. 6:1986;669-676.
164. Nau H., Scott W. J. J. Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature. 323:1986;276-278.
165. Nau H., Hauck R.-S., Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmac. Toxic. 69:1991;310-321.
166. Nau, H., Siemes, H., Fisher, E., Pund, R., Wittfoht, W. and Drews, E. (1991b) Valproic acid metabolite patterns in 195 children with epilepsy: effect of age, dose, comedication, duration of treatment, and clinical factors. In: Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity, pp. 65-74. Eds. R. H. Levy and J. K. Penry. Raven Press, New York.
167. Nilsson M., Hansson E., Ronnback L. Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem. Res. 17:1992;327-332.
168. Nutt D. J., Cowen P. J., Little H. J. Unusual interactions of benzodiazepine receptor antagonists. Nature. 295:1982;436.
169. Olpe H. R., Steinmann M. W., Pozza M. F., Brugger F., Schmutz M. Valproate enhances GABA - A mediated inhibition of locus coeruleus neurons in vitro. Naunyn-Schmiedeberg's Arch. Pharmac. 338:1988;655-657.
170. Olsen R. W. The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol. Cell. Biochem. 39:1981;261-279.
171. Patsalos P. N., Lascelles P. T. Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximide, and sulthiame in the rat. J. Neurochem. 36:1981;688-695.
172. Perlman B. J., Goldstein D. B. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Mol. Pharmac. 26:1984;83-89.
173. Perreault P., Tancredi V., Avoli M. Failure of the antiepileptic drug valproic acid to modify synaptic and non-synaptic responses of Ca1 hippocampal pyramidal cells "in vitro" Epilepsy Res. 3:1989;227-231.
174. Perucca, E. and Richens, A. (1985) Antiepileptic drug interactions. In: Antiepileptic Drugs, pp. 831-856. Eds. H.-H. Frey and D. Janz. Springer, Berlin.
175. Petersen E. N. DMCM: a potent convulsive benzodiazepine receptor ligand. Eur. J. Pharmac. 94:1983;117-124.
176. Petty F. GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. 34:1995;275-281.
177. Phillips N. I., Fowler L. J. The effects of sodium valproate on γ-aminobutyrate metabolism and behavior in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochem. Pharmac. 31:1982;2257-2261.
178. Pinder R. M., Brogden R. N., Speight T. M., Avery G. S. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 13:1977;81-123.
179. 35S]t-butylbicyclophosphorothionate binding in vitro and ex vivo. Pharmac. Toxic. 61:1987;103-106.
180. Roderfeld H.-J., Altrup U., Düsing R., Lorra C., Madeja M., Mußhoff U., Pongs O., Speckmann E.-J., Spener F. Effects of the antiepileptic drug valproate on cloned voltage-dependent potassium channels. Pflügers Arch. 426(Suppl.):1994;R32.
181. Rogawski M. A., Porter R. J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental
182. Rohlfs A., Rundfeldt C., Koch R., Löscher W. A comparison of the effects of valproate and its major active metabolite E-2-en-valproate on single unit activity of substantia nigra pars reticulata neurons in rats. J. Pharmac. exp. Ther. 277:1996;1305-1314.
183. Ross S. M., Craig C. R. Studies on γ-aminobutyric acid transport in cobalt experi mental epilepsy in the rat. J. Neurochem. 36:1981;1006-1011.
184. Rotiroli D., Palella B., Losi E., Nistico G., Caputi A. P. Evidence that a GABAergic mechanism influences the development of DOCA-salthypertension in the rat. Eur. J. Pharmac. 83:1982;153-154.
185. Rowley H. L., Marsden C. A., Martin K. F. Differential effects of phenytoin and sodium valproate on seizure-induced changes in gamma-aminobutyric acid and glutamate release in vivo. Eur. J. Pharmac. 294:1995;541-546.
186. Rumbach L., Mutet C., Cremel G., Marescaux C. A., Micheletti G., Warter J. M., Waksman A. Effects of sodium valproate on mitochondrial membranes: electron paramagnetic resonance and transmembrane protein movement studies. Mol. Pharmac. 30:1986;270-273.
187. Schachter S. C. Review of the mechanisms of action of antiepileptic drugs. CNS Drugs. 4:1995;469-477.
188. Scheuer M. L., Pedley T. A. The evaluation and treatment of seizures. N. Engl. J. Med. 323:1990;1468-1474.
189. Schmidt D., Gram L. Monotherapy versus polytherapy in epilepsy: a reappraisal. Cns. Drugs. 3:1995;194-208.
190. Schmitz D., Zhang C. L., Chatterjee S. S., Heinemann U. Effects of methysticin on three different models of seizure like events studied in rat hippocampal and entorhinal cortex slices. Naunyn-Schmiedeberg's Arch. Pharmac. 351:1995;348-355.
191. Schobben F., van der Kleijn E., Vree T. B. Therapeutic monitoring of valproic acid. Ther. Drug Monitor. 2:1980;61-71.
192. Schwartzkroin P. A. Hippocampal slices in experimental and human epilepsy. Adv. Neurol. 44:1986;991-1010.
193. 2-valproate and valproate in rats. Epilepsia. 32:1991;232-241.
194. Shinnar S., Berg A. T. Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? Epilepsia. 37:1996;701-708.
195. Shuto K., Nishigaki T. The pharmacological studies on sodium dipropylacetate anticonvulsant activities and general pharmacological actions. Pharmacometrics. 4:1970;937-949. (in Japanese).
196. Siemes H., Nau H., Schultze K., Wittfoht W., Drews E., Penzien J., Seidel U. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia. 34:1993;332-346.
197. Silberstein, S. D. (1998) Valproate in the treatment of headache. In: Valproate. Ed. W. Löscher. Birkhäuser, Basel.
198. Silver J. M., Shin C., McNamara J. O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilepsy. Ann. Neurol. 29:1991;356-363.
199. Similae S., von Wendt L., Linna S. L., Saukkonen A. L., Huhtaniemi I. Dipropylacetate and hyperglycemia. Neuropaediatrie. 1:1979;158-160.
200. Simler S., Randrianarisoa H., Lehman A., Mandel P. Effects du di-n-propylacétate sur les crises audiogènes de la souris. J. Physiol. (Paris). 60:1968;547.
201. Simler S., Ciesielski L., Klein M., Gobaille S., Mandel P. Sur le mècanisme d'action d'un anticonvulsivant, le dipropylacétate de sodium. C.R. Soc. Biol. (Paris). 175:1981;114-119.
202. Simler S., Ciesielski L., Klein M., Mandel P. Anticonvulsant and antiaggressive properties of di-n-propylacetate after repeated treatment. Neuropharmacology. 21:1982;133-140.
203. Simler S., Puglisi-Allegra S., Mandel P. Effects of n-di-propylacetate on aggressive behavior and brain GABA level in isolated mice. Pharmac. Biochem. Behav. 18:1983;717-720.
204. Slater G. E., Johnston D. Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia. 19:1978;379-384.
205. Snead O. C., Bearden L. J., Pegram V. Effect of acute and chronic anticonvulsant administration on endogenous γ-hydroxybutyrate in rat brain. Neuropharmacology. 19:1980;47-52.
206. Snead O. C. γ-Hydroxybutyrate model of generalized absence seizures: further characterization and comparison with other absence models. Epilepsia. 29:1988;361-377.
207. Sokolova S., Schmitz D., Zhang C. L., Löscher W., Heinemann U. Comparison of effects of valproate and trans-2-en-valproate on different forms of epileptiform activity in rat hippocampal and temporal cortex slices. Epilepsia. 39:1998;251-258.
208. 35S]-Butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled to γ-aminobutyric acid-A and ion regognition sites. Mol. Pharmac. 23:1983;326-336.
209. Swinyard, E. A. (1964) The Pharmacology of Dipropylacetic Acid Sodium with Special Emphasis on its Effects on the Central Nervous System, pp. 1-25. University of Utah, College of Pharmacy, Salt Lake City, Utah.
210. Taberner P. V., Charington C. B., Unwin J. W. Effects of GAD and GABA-T inhibitors on GABA metabolism in vivo. Brain Res. Bull. 5(Suppl. 2):1980;621-625.
211. Taylor C. P., Vartanian M. G., Andruszkiewicz R., Silverman R. B. 3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Res. 11:1992;103-110.
212. Thomson S. M. Consequence of epileptic activity in vitro. Brain Pathol. 3:1993;413-419.
213. 3H]dihydroxypicrotoxinin binding sites at the benzodiazepine-GABA receptor ionophore complex. Brain Res. 223:1981;218-222.
214. Timmerman W., Westerink B. H. C. Brain microdialysis of GABA and glutamate: what does it signify? Synapse. 27:1997;242-261.
215. Timmermann W., Zwaveling J., Westerink B. H. C. Characterization of extracellular GABA in the substantia nigra reticulata by means of brain microdialysis. Naunyn-Schmiedeberg's Arch. Pharmac. 345:1992;661-665.
216. Trabucchi M., Cerri C., Spano P. F., Kumakura K. Guanosine 3′,5′-monophosphate in the CSF of neurological patients. Arch. Neurol. 34:1977;12-13.
217. Turner A. J., Whittle S. R. Sodium valproate, GABA and epilepsy. Trends Pharmac. Sci. 1:1980;257-260.
218. Watson D. G., Watterson J. M., Lenox R. H. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J. Pharmac. exp. Ther. 285:1998;307-316.
219. Ueki S., Araki Y., Watanabe S. Changes in sensitivity of mice to anticonvulsant drugs following bilateral olfactory bulb ablations. Jpn. J. Pharmac. 27:1977;183-192.
220. Vajda F. J., Donnan G. A., Phillips J., Bladin P. F. Human brain, plasma and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy. Neurology. 31:1981;486-487.
221. Van den Berg R. J., Kok P., Voskuyl R. A. Valproate and sodium currents in cultured hippocampal neurons. Exp. Brain Res. 93:1993;279-287.
222. Vandongen A. M. J., vanerp M. G., Voskuyl R. A. Valproate reduces excitability by blockade of sodium and potassium conductance. Epilepsia. 27:1986;177-182.
223. Vayer P., Cash C. D., Maitre M. Is the anticonvulsant mechanism of valproate linked to its interaction with the cerebral γ-hydroxybutyrate system? Trends Pharmac. Sci. 9:1988;127-129.
224. Vellucci S. V., Webster R. A. The role of GABA in the anticonflict action of sodium valproate and chlordiazepoxide. Pharmac. Biochem. Behav. 21:1984;845-851.
225. Vriend J. P., Alexiuk N. A. M. Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone balb/c mice. Mol. Chem. Neuropathol. 27:1996;307-324.
226. Walden J., Altrup U., Reith H., Speckmann E.-J. Effects of valproate on early and late potassium currents of single neurons. Eur. Neuropsychopharmac. 3:1993;137-141.
227. Walton N. Y., Treiman D. M. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 12:1992;199-205.
228. Wamil A. W., McLean M. J. Effect of anticonvulsant medications on responses to NMDA by mouse central neurons in cell culture. Epilepsia. 32(Suppl. 3):1991;42.
229. Wamil A. W., Löscher W., Mclean M. J. Trans-2-en-valproic acid limits action potential firing frequency in mouse central neurons in cell culture. J. Pharmac. exp. Ther. 280:1997;1349-1356.
230. White H. S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 38:1997;S9-S17.
231. Whittle S. R., Turner A. J. Effects of the anticonvulsant sodium valproate on γ-aminobutyrate and aldehyde metabolism in ox brain. J. Neurochem. 31:1978;1453-1459.
232. Whittle S. R., Turner S. J. Effects of anticonvulsants on the formation of γ-hydroxybutyrate from γ-aminobutyrate in rat brain. J. Neurochem. 38:1982;848-851.
233. Wikinski S. I., Acosta G. B., Rubio M. C. Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain. Gen. Pharmac. 27:1996;635-638.
234. Wolf R., Tscherne U., Emrich H. M. Suppression of preoptic GABA release caused by push-pull-perfusion with sodium valproate. Naunyn-Schmiedeberg's Arch. Pharmac. 338:1988;658-663.
235. Worms, P. and Lloyd, K. G. (1981) Functional alterations of GABA synapses in relation to seizures. In: Neurotransmitters, Seizures, and Epilepsy, pp. 37-46. Eds. P. L. Morselli, K. G. Lloyd, W. Löscher, B. S. Meldrum and E. H. Reynolds. Raven Press, New York.
236. Zeise M. L., Kasparaow S., Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 544:1991;345-348.
237. Zhang C. L., Dreier J. P., Heinemann U. Paroxysmal epileptiform discharges in temporal lobe slices after prolonged exposure to low magnesium are resistant to clinically used anticonvulsants. Epilepsy Res. 20:1995;105-111.
238. Zimmer R., Teelken A. W., Gündürewa M., Rüther E., Cramer H. Effect of sodium valproate on CSF GABA, cAMP, cGMP and homovanillic acid levels in men. Brain Res. Bull. 5(Suppl. 2):1980;585-588.